ARCHIVES

Gleevec Improves Survival Of CML In Accelerated Phase

This article is from The Cancer Letter archive.

Vol. 25 No. 12 | December 27, 2002

Download PDF Visit The Full Archive

Related Articles

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

December 26, 2014

Barbara Rimer Named NCAB Chairman; First Women Appointed To Lead Board

September 16, 1994

NCAB Asks Government To Take Steps Aimed at Reducing Health Hazards From Cigarettes

December 21, 1973

In Brief: House Passes appropriations Bill; Senate Markup in Late Summer; Kirschstein Acting NIH Director

July 9, 1993

NIH Reconsiders Closing A Meeting Of Advisory Group

January 13, 1995

MAP Says It Will Continue Operating With Private Funds

April 18, 1986